Lilly France

Lilly France lists 2 GLP-1 packages in the FDA NDC directory, covering dulaglutide.

By Sam Reed · Founder and data lead

Lilly France appears on 2 GLP-1 packages in the FDA National Drug Code directory, covering dulaglutide. The labeler is the firm whose name is on the package. It is not necessarily the manufacturer, and it is never the telehealth programme that sells you the prescription.

The listing

Every package it lists

Product	Ingredient	Form	Package	Category
—	Dulaglutide	INJECTION, SOLUTION	45 SYRINGE in 1 TRAY (62381-1433-1) / .5 mL in 1 SYRINGE	DRUG FOR FURTHER PROCESSING
—	Dulaglutide	INJECTION, SOLUTION	45 SYRINGE in 1 TRAY (62381-1434-1) / .5 mL in 1 SYRINGE	DRUG FOR FURTHER PROCESSING

Source: FDA National Drug Code directory. A listing is a registration, not an FDA endorsement of the product.

Data sources · cited with retrieval dates

FDA warning lettersPublished compliance actions, updated weekly
FDA registered outsourcing facilities503B register, with inspection and enforcement status
FDA National Drug Code directoryLabeler, product and package listings

NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.